Bayer : Q1 EBITDA below expectations – guidance only confirmed at the lower end due to glyphosate price risks
>Low glyphosate prices and high procurement costs in Pharma burdened Q1 results - At a group level, Bayer’s Q1 2023 figures came in below expectations. While sales of € 14.4bn (-1.7%), were roughly in line with our (€ 14.4bn) and consensus estimates (€ 14.6n), the group’s EBITDA of € 4,471m (-14.9%) came in -1.3% below our estimates (€4,532m) and -3.5% below the consensus (€ 4.632m). The strong EBITDA decline vs Q1 2022 was driven by both segments, the Crop Science d...Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.